Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes

Haematologica

Volumn 98, Issue 2, 2013, Pages 179-184

  Harris, Andrew C ^a   Kitko, Carrie L ^a   Couriel, Daniel R ^a   Braun, Thomas M ^a   Choi, Sung W ^a   Magenau, John ^a   Mineishi, Shin ^a   Pawarode, Attaphol ^a   Yanik, Gregory ^a   Levine, John E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CD56 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETANERCEPT; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID;

5Q- SYNDROME; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMOTHERAPY; CHROMOSOME 7Q; CYTOGENETICS; FEMALE; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MORTALITY; MYELOABLATIVE CONDITIONING; RADIATION DOSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; WHOLE BODY RADIATION; ADOLESCENT; AGED; ALLOTRANSPLANTATION; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875307915     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.073189     Document Type: Article

References (24)

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. Available at:http://www.cibmtr.org.
2. Craddock CF. Full-intensity and reducedintensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant. 2008;41(5):415-23.
3. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant. 2009;44(12):769-77.
4. Meijer E, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. Semin Oncol. 2008;35(4):449-57.
5. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;84(11):3603-12.
6. Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2005:151-5.
7. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989;7(1):50-7.
8. Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol. 1999;17(2):45-52.
9. Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma. 2006;47(9):1754-67.
10. Lee KH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant. 2003;32(8):835-42.
11. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer. 1999;85(3):608-15.
12. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 1995;13(7):1800-16.
13. Gray RJ. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics. 1988;16(3): 1141-54.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
15. Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004;28(10): 1007-11.
16. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 1987;2 (3):243-58.
17. Gale RP, Horowitz MM, Weiner RS, Ash R, Atkinson K, Babu R, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995;16(2):203-8.
18. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol. 2002;117(4):914-23.
19. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, et al. Impact of cytogenetics on outcome of de novo and therapy- related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13(6):655-64.
20. Simpson DR, Nevill TJ, Shepherd JD, Fung HC, Horsman DE, Nantel SH, et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant. 1998;22(3):259-64.
21. Szomor A, Passweg JR, Tichelli A, Hoffmann T, Speck B, Gratwohl A. Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma (chloroma) after allogeneic bone marrow transplantation. Ann Hematol. 1997;75(5-6):239-41.
22. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant. 2000; 26(9):1011-5.
23. Solh M, DeFor TE, Weisdorf DJ, Kaufman DS. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2012;18(1):106-12.
24. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, et al. Lowdose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115(9):1899-905.